Drugs / I-124 evuzamitide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06788535 | Jan 2025 → Apr 2026 | amyloidosis | Sharmila Dorbala | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | I-124 evuzamitide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06788535 ↗ |
| Modality | Diagnostic / imaging agent | “as an Imaging Agent for the Diagnosis of Cardiac Amyloidosis Using Positron Emission Tomography Computed Tomography (PET/CT)” NCT06788535 ↗ |
| Route | Intravenous | “I-124 evuzamitide administered intravenously” NCT06788535 ↗ |